Form 4 for IMAX IMAX CORP
Accepted 2026-08-20 17:37:45 ET · period of report 2026-08-18 · accession 0001214659-26-010664 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-20 17:37 | 2026-08-18+ | IMAX | GELFOND RICHARD L | CEO, Dir | C - Cnv Deriv | $31.90 | +356.8K | 970.5K | +58% | +$11.38M |
| DMT | 2026-08-20 17:37 | 2026-08-18+ | IMAX | GELFOND RICHARD L | CEO, Dir | S - Sale | $52.51 | -456.8K | 665.0K | -41% | -$23.98M |
| DMT | 2026-08-20 17:37 | 2026-08-18+ | IMAX | GELFOND RICHARD L | CEO, Dir | C - Cnv Deriv | $31.90 | -356.8K | 975.7K | -27% | -$11.38M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | common shares | 2026-08-18 | C | A | 151,253 | $31.90 | 916,255 | D | — | — | (F1) Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated May 19, 2026. |
| 2 | Common | common shares | 2026-08-18 | S | D | 151,253 | $51.00 | 765,002 | D | — | — | (F2) Represents the sale of converted common shares pursuant to a 10b5-1 Plan dated May 19, 2026. |
| 3 | Common | common shares | 2026-08-19 | C | A | 205,504 | $31.90 | 970,506 | D | — | — | (F1) Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated May 19, 2026. |
| 4 | Common | common shares | 2026-08-19 | S | D | 205,504 | $53.27 | 765,002 | D | — | — | (F2) Represents the sale of converted common shares pursuant to a 10b5-1 Plan dated May 19, 2026. |
| 5 | Common | common shares | 2026-08-20 | S | D | 100,000 | $53.23 | 665,002 | D | — | — | |
| 6 | Derivative | stock options (to buy) | 2026-08-18 | C | D | 151,253 | $31.90 | 1,181,158 | D | $31.90 · — to 2027-01-03 | 151,253 common shares | (F3) These options were issued in 2017 and are set to expire on January 3, 2027. (F4) The stock options became exercisable in nine installments: 39,640 on each of May 1, 2017, September 1, 2017, May 1, 2018, December 31, 2018, September 1, 2019 and December 31, 2019, and 39,639 on each of December 31, 2017, September 1, 2018 and May 1, 2019. (F5) This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 975,654, 231,562 and 665,002, respectively. |
| 7 | Derivative | stock options (to buy) | 2026-08-19 | C | D | 205,504 | $31.90 | 975,654 | D | $31.90 · — to 2027-01-03 | 205,504 common shares | (F3) These options were issued in 2017 and are set to expire on January 3, 2027. (F4) The stock options became exercisable in nine installments: 39,640 on each of May 1, 2017, September 1, 2017, May 1, 2018, December 31, 2018, September 1, 2019 and December 31, 2019, and 39,639 on each of December 31, 2017, September 1, 2018 and May 1, 2019. (F5) This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 975,654, 231,562 and 665,002, respectively. |